Table 3.
Proportion and absolute number of paediatric (<15 years) ART clients on MMD in 21 PEPFAR‐supported countries (October 2019–December 2020)
| Quarter | Paediatric clients on ART | 3–5MMD (%) | 6MMD (%) | Total MMD (%) |
|---|---|---|---|---|
| Q4 2019 | 524,546 | 127,261 (24%) | 15,319 (3%) | 142,580 (27%) |
| Q1 2020 | 525,128 | 165,620 (32%) | 16,055 (3%) | 181,675 (35%) |
| Q2 20201 | 531,538 | 238,561a (45%) | 32,423b (6%) | 270,984c (51%) |
| Q3 2020 | 537,126 | 242,968 (45%) | 38,792 (7%) | 281,760 (52%) |
| Q4 2020 | 532,239 | 244,351 (46%) | 39,814 (7%) | 284,165 (53%) |
1Two‐proportion Z‐test comparing MMD % for Q2 2020 (COVID‐19) versus Q4 2019 (pre‐COVID‐19): (a) for 3–5 MMD, p < 0.001; (b) for 6MMD, p <0.001; and (c) for total MMD, p < 0.001.